Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Chemotherapy vs Chemotherapy in R/R Classical Hodgkin Lymphoma
NCT05711628Phase 3Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Aug 2023
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by National Cancer Institute. Planned start Aug 2023; status: withdrawn.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05711628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711628.